Resource Summary Report

Generated by dkNET on Sep 6, 2026

HK-2 [Human kidney]

RRID:CVCL_0302
Type: Cell Line

Proper Citation

Ubigene Cat# YC-C140, RRID:CVCL_0302

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0302

Proper Citation: Ubigene Cat# YC-C140, RRID:CVCL_0302

Description: Cell line HK-2 [Human kidney] is a Transformed cell line with a species of origin Homo sapiens (Human)

Sex: Male

Defining Citation: PMID:8127021, PMID:20215515, PMID:20555413, PMID:22949125, PMID:28489074, PMID:30894373, PMID:31068700, PMID:33122286

Comments: Population: Caucasian., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Transformed cell line

Organism: Homo sapiens (Human)

Name: HK-2 [Human kidney]

Synonyms: Hk-2, HK2, Human Kidney-2

Cross References: BTO:BTO_0003575, CLO:CLO_0003771, EFO:EFO_0022529, MCCL:MCC:0000193, AddexBio:T0011004/4929, ATCC:CRL-2190, BCRC:60097, BioGRID_ORCS_Cell_line:1711, BioSample:SAMN03472562, cancercelllines:CVCL_0302, CCRID:3101HUMSCSP511, CCRID:4201HUM-CCTCC00152, CCTCC:GDC0152, Cell_Model_Passport:SIDM01818, ChEMBL-Cells:CHEMBL4295396, ChEMBL-Targets:CHEMBL4296428, CLS:305021, Cosmic:2520628, DepMap:ACH-001087, ENCODE:ENCBS188NWH, GEO:GSM827261, GEO:GSM4009069, GEO:GSM4009073, KCB:KCB 200815YJ, KCLB:22190, Lonza:769, PharmacoDB:HK2_545_2019, Progenetix:CVCL_0302, PubChem_Cell_line:CVCL_0302, Ubigene:YC-C140, Wikidata:Q54889732

ID: CVCL_0302

Vendor: Ubigene

Catalog Number: YC-C140

Record Creation Time: 20250130T071726+0000

Record Last Update: 20260905T184028+0000

Ratings and Alerts

No rating or validation information has been found for HK-2 [Human kidney].

No alerts have been found for HK-2 [Human kidney].

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 1900 mentions in open access literature.

Listed below are recent publications. The full list is available at dkNET .

Koh J, et al. (2026) ZNF395 Is a Hypoxia-Responsive Regulator of Mitochondrial Glutaminolysis in Clear Cell Renal Cell Carcinoma. Cancer research, 86(7), 1676.

Chen Y, et al. (2026) USP15 stabilizes c-Myc to drive sunitinib resistance by suppressing cuproptosis in clear cell renal cell carcinoma. Cell reports, 45(5), 117328.

Shi H, et al. (2026) OSCAR functions as a collagen I receptor to suppress hippo signaling and reprogram lipid metabolism in clear-cell renal cell carcinoma. Cell death & disease, 17(1).

Kudo K, et al. (2026) A kidney-protective mechanism via cellular oxidative stress reduction induced by CD5L protein. Cell death discovery, 12(1).

Jiang Y, et al. (2026) Ultrasmall Au10-12 Nanoclusters: A Novel Platform for 223Ra-Targeted Tumor ?-Therapy. Exploration (Beijing, China), 6(2), 70144.

Zhu X, et al. (2026) KIAA1429 promotes clear cell renal cell carcinoma progression by regulating MYC mRNA stability. iScience, 29(4), 115198.

Wang B, et al. (2026) Qingxin Lianzi Yin Improves Chronic Kidney Disease by Targeting Ferroptosis via the TLR4/HIF-1? Pathway. Mediators of inflammation, 2026(1), e7440641.

Dier AK, et al. (2026) Tubular basement membrane damage promotes renal fibrosis via an ETV5/TGFB1/SOX9 axis in proximal tubular epithelial cells after acute kidney injury. Cellular signalling, 146, 112684.

Zeng C, et al. (2026) Imidazole Propionate Induces Kidney Damage by Activating the ROS-NLRP3 Signaling Pathway Through mTOR Inhibition of Autophagy in Renal Tubular Epithelial Cells. Mediators of inflammation, 2026, 2457371.

Yang Y, et al. (2026) Curcumin regulates ferroptosis by activating ?7 nicotinic acetylcholine receptor to improve sepsis-induced acute kidney injury. Renal failure, 48(1), 2657652.

Bian X, et al. (2026) Senolytics, dasatanib plus quercetin, reduce kidney inflammation, senescent cell abundance, and injury while restoring geroprotective factors in murine diabetic kidney disease. EBioMedicine, 124, 106124.

Huang F, et al. (2026) SLC38A6 expression in renal tubular cells accelerates cisplatin-induced acute kidney injury by promoting cell apoptosis. The FEBS journal.

Su L, et al. (2026) ENPP1 blockade with a humanized monoclonal antibody enhances renal repair after acute kidney injury. Cell stem cell, 33(7), 1110.

Zhang D, et al. (2026) Activation of TLR4-NF-?B signaling in renal tubular epithelial cells facilitates renal allograft fibrosis by inhibiting peroxisome biogenesis. Biochimica et biophysica acta. Molecular basis of disease, 1872(2), 168066.

Duan F, et al. (2026) Inhibition of GRK2 mitigates cisplatin-induced acute and chronic nephrotoxicity by targeting the NADPH oxidase 4/oxidative stress axis. British journal of pharmacology, 183(12), 3149.

Pan G, et al. (2026) Enhancing platinum-based chemotherapy efficacy and safety through combination therapy-mediated remodeling of autophagic homeostasis in gastric cancer. Cell death & disease, 17(1).

Gong G, et al. (2026) NDUFA5 deficiency promotes renal inflammation in diabetic nephropathy via mitochondrial ROS signaling. iScience, 29(5), 115555.

Kandel R, et al. (2026) Transcriptomics reveal dysregulated genes during folic acid-induced acute injury and fibrosis in kidney and their attenuation by antioxidant N-acetyl cysteine. American journal of physiology. Cell physiology, 331(1), C177.

Wang C, et al. (2026) USP18 promotes clear cell renal cell carcinoma progression by regulating the ubiquitination and stability of YBX3. iScience, 29(5), 115808.

Li Y, et al. (2026) Integrating Bulk and Single-Cell RNA-Seq Reveals Glycolysis-Associated Macrophages and Its Related Tumor Subgroup Signatures to Predict Prognosis and Therapy in Clear Cell Renal Cell Carcinoma. Human mutation, 2026, 3125551.